RV 144

Principal Investigator(s):Supachai Rerks-Ngarm
Objective:To determine whether immunizations with an integrated combination of ALVAC-HIV (vCP1521) boosted by AIDSVAX gp120 B/E prevent HIV infection in healthy Thai volunteers.Results: The ALVAC-HIV and AIDSVAX B/E vaccine regimen was found to be safe, well tolerated and suitable for potential large-scale use in Thailand.Last updated September 14, 2022
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionALVAC-HIV vCP1521 + AIDSVAX 1cc injected into left deltoid muscle at day 0,weeks 4, 12, 24 Prime/Boost Vaccination
Mode of DeliveryIntramuscular
Official Code: NCT00223080
Trial Sponsors: EMMES, Henry M Jackson Foundation, Sanofi Pasteur MSD, Thailand Ministry of Health, US Military HIV Research Program, VaxGen, Walter Reed Army Institute of Research (WRAIR)
Start Date
End Date
October 1, 2003
June 30, 2009
Age range: 18 Years ↔ 30 Years
Population:Cisgender Men, Cisgender Women